Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Caplin Point gains on receiving USFDA approval for Ketorolac Tromethamine Injection

20-Sep2017

Caplin Point gains on receiving USFDA approval for Ketorolac Tromethamine Injection

Caplin Point Laboratories is currently trading at Rs. 732.60, up by 5.65 points or 0.78% from its previous closing of Rs. 726.95 on the BSE.

The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 745.00 and Rs. 721.90 respectively. So far 17,104 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 783.90 on 07-Aug-2017 and a 52 week low of Rs. 240.00 on 29-Sep-2016.

Last one week high and low of the scrip stood at Rs. 745.00 and Rs. 685.55 respectively. The current market cap of the company is Rs. 5,536.00 crore.

The promoters holding in the company stood at 69.06%, while Institutions and Non-Institutions held 5.86% and 25.08% respectively.

Caplin Point Laboratories has received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. Ketorolac Tromethamine Injection is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.

Ketorolac Tromethamine Injection has been developed at Caplin Point and will be manufactured at Caplin's FDA approved site. Cycle has selected Virtus Pharmaceuticals, LLC (Virtus) as the importer and distributor of Ketorolac Tromethamine Injection in the U.S.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.



Related News

View all news

SBI Life shines on reporting 15% rise in Q3 net profit

SBI Life Insurance Company is currently trading at Rs. 635.45, up by 15.65 points or 2.53% from its previous closing of Rs. 619.80 on the BSE.The scrip opened at Rs. 621.00 and has touched a high and low......

Reliance Industries zooms on the bourses

Reliance Industries is currently trading at Rs. 1219.00, up by 36.05 points or 3.05% from its previous closing of Rs. 1182.95 on the BSE.The scrip opened at Rs. 1193.90 and has touched a high and low of......

Infosys surges on the BSE

Infosys is currently trading at Rs. 746.30, up by 15.30 points or 2.09% from its previous closing of Rs. 731.00 on the BSE.The scrip opened at Rs. 733.00 and has touched a high and low of Rs. 750.70 and......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......